As FTC and PTC also differ genetically i.e., RAS mutations predominate in FTC whereas mutant BRAF is much more frequent in PTC, it is assumed although yet unproven that the archetypical tumor growth pattern – follicular versus papillary – depends on mutation identity and potentially the graded signaling output of the MAPK pathway that differs in response to constitutive activation by RAS or BRAF. This evidence concerns the gene BRAF and neoplasm.